Biota Pharmaceuticals to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference
12 December 2015 - 8:01AM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical
company focused on the discovery and development of direct-acting
antivirals that address infections that have limited therapeutic
options, announced today that Biota's executive team will
participate in the Guggenheim Securities 3rd Annual Boston
Healthcare Conference being held at the Langham Hotel on Tuesday,
December 15, 2015 in Boston, MA.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and
development of direct-acting antivirals to treat infections that
have limited therapeutic options and affect a significant number of
patients globally. The Company has three product candidates in
active clinical development: These include vapendavir, an oral
treatment for human rhinovirus infections in moderate-to-severe
asthmatics currently being evaluated in the Company's ongoing Phase
2b SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in
Phase 1 development for the treatment and prevention of respiratory
syncytial virus (RSV) infections; and BTA074, a topical antiviral
treatment in Phase 2 development for condyloma caused by human
papillomavirus types 6 & 11. For additional information about
the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
CONTACT: Mark Colonnese
Executive Vice President and Chief Financial Officer
(678) 221-3352
m.colonnese@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024